Earnings Feed
Start Free
|4Feb 3, 6:54 PM ET

Anderson Karen M. 4

4 · Centessa Pharmaceuticals plc · Filed Feb 3, 2026

Research Summary

AI-generated summary of this filing

Updated

Centessa (CNTA) CPO Karen Anderson Receives RSU Award, Sells 10,606 Shares

What Happened Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals (CNTA), had a small disposition and two awards reported. On 2026-02-01 she had 10,606 shares withheld/sold at $24.57 each to cover tax obligations (gross proceeds/value = $260,589). On 2026-02-02 she was awarded/received 29,000 shares (no cash price) and a 117,000-share derivative award (no cash price), both reported as grants/awards.

Key Details

  • Transactions reported: 2026-02-01 (10,606 shares withheld/sold at $24.57; $260,589) and 2026-02-02 (29,000 shares granted; 117,000 derivative award granted; both $0 cash price).
  • Shares owned after transaction: not specified in the filing.
  • Notable footnotes from the filing:
    • F1: Ordinary Shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
    • F2: The 10,606-share disposition represents shares withheld by the issuer to cover tax withholding on vesting.
    • F3: Certain awards are Restricted Share Units (RSUs) under the company plan; RSUs vest/settle in four equal annual installments with the first vesting on Feb 2, 2027.
    • F4: Another award is subject to 1/48th monthly vesting, with the first installment vesting on Mar 2, 2026.
  • Filing info: Form 4 filed 2026-02-03 (Accession 0001470831-26-000086); this appears to be filed timely. Exhibit 24.2 (Substitute Power of Attorney) is attached.

Context

  • The 10,606-share sale was a tax-withholding disposition (routine administrative action), not an opportunistic open‑market sale. The grants (RSUs / derivative award) are compensation awards that vest over time — they do not represent an immediate market purchase or sale. For retail investors, awards indicate executive compensation alignment with the company but are not the same signal as an insider buying stock with cash.

Insider Transaction Report

Form 4
Period: 2026-02-01
Centessa Pharmaceuticals plcCNTA
Anderson Karen M.
Chief People Officer
Transactions
  • Tax Payment

    Ordinary Shares

    [F1][F2]
    2026-02-01$24.57/sh−10,606$260,589→ 43,716 total
  • Award

    Ordinary Shares

    [F1][F3]
    2026-02-02+29,000→ 72,716 total
  • Award

    Share Option (right to buy)

    [F4][F1]
    2026-02-02+117,000→ 117,000 total
    Exercise: $25.19Exp: 2036-02-02→ Ordinary Shares (117,000 underlying)
Footnotes (4)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
  • [F3]The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
  • [F4]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.
Signature
/s/ Raphael Deferiere, attorney-in-fact|2026-02-03

Documents

2 files